There certainly is an element of risk included. Yet, personally I deem it pretty small as the main idea of sozinibercept - that‘s blocking the VEGF-C pathway - holds true for all anti-VEGF-A agents - be it Lucentis, Eylea, Avastin, Beovu or Fabysmo - as they all lead to an unintended upregulation of VEGF-C as the main escape pathway of progressing angionesis.
There certainly is an element of risk included. Yet, personally...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
82.5¢ |
Change
0.015(1.85%) |
Mkt cap ! $1.015B | |||
| Open | High | Low | Value | Volume |
| 84.5¢ | 84.5¢ | 80.0¢ | $2.835M | 3.473M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 17359 | 82.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 83.0¢ | 106026 | 2 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |